CALGARY, AB, April 29, 2024 /CNW/ - Nanalysis Scientific Corp. ("the Company") (TSXV:NSCI) (OTCQX:NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications announces fourth quarter and full year results for the period ending on December 31, 2023. Chief Executive Officer, Sean Krakiwsky and Chief Financial Officer, Randall McRae will host a conference call at 5 P.M. Eastern Time today to discuss the results. A second call will be held for European investors at 8:30am ET tomorrow, Tuesday, April 30th. All interested parties are invited to join these calls.     "As noted in our previous release dated February 6, 2024, we are very pleased with how our businesses ramped up in second half of 2023 and we closed out the year with good momentum which has carried into the current year," said Sean Krakiwsky, Founder and CEO of Nanalysis.  "Our benchtop sales have regained stride and the personnel changes that we made earlier in the year are producing good results that we expect to continue going forward.  Our security services segment completed taking over all basic services on the Company's Airport Security Project early in 2024, and this project will continue its expansion and roll-out, building towards full revenue run rate through the year.  Additionally, in 2023 we had significant up-front training costs which contracted our margins.  In 2024, we expect that to be significantly reduced  and look for security services margins to improve throughout the year."  Financial highlights for the three months ended December 31, 2023: Three months ended December 31 ($000's)  2023 2022 ($) Change Product sales 5,450 5,893 (443) Service revenue 4,350 1,310 3,040 Total sales and revenue 9,800 7,203 2,597 Gross margin - product sales 48 % 32 % 16 % Gross margin - service revenue -21 % -50 % 29 % EBITDA (774) (2,532) 1,758 Net loss (2,123) (3,292) 1,169 For the three months ended December 31, 2023, the Company reported consolidated revenue of $9,800, an increase of $2,597K or 36% from the comparative period in 2022.  This includes $5,450K in product sales and $4,350K of service revenue related to security services. Gross margin percentage on product sales was 48% for the three months ended December 31, 2023.  Improvement in gross margin percentage for Benchtop NMR is materializing as sales have improved in the second half of the year and reductions in the manufacturing labour force in late Q2 have begun to positively affect margins. Service gross margin percentage in the quarter was (21%) as the Company accelerated its training schedule for the Airport Security Project and began expensing wages related to airports that were in service.  Management expects service gross margin percentage to improve significantly as the Airport Security Project is phased-in to full capacity and revenue scale up continues in 2024. EBITDA loss for the three months ended December 31, 2023, was $774K versus a $2,532K EBITDA loss in the same period last year. Net loss for the three months ended was $2,123K as compared to the three-month loss for December 31, 2022, of $3,292K. Financial highlights for the twelve months ended December 31, 2023: Twelve months ended December 31 ($000's)  2023 2022 ($) Change Product sales 16,342 21,588 (5,246) Service revenue 12,124 3,233 8,891 Total sales and revenue 28,466 24,821 3,645 Gross margin percentage - product sales 41 % 49 % -8 % Gross margin percentage - service revenue -23 % -1 % -22 % EBITDA